Allogeneic stem cell transplantation has become an important option in the curative treatment of many patients with malignant and non-malignant systemic diseases. Non-availability of HLA identical donors can limit access to this life-saving treatment, especially in ethnic minority patients, for whom identical donors are often not available [1,2]. For many years, a central aim has been the development of stem cell transplantation across the HLA barrier and the use of haploidentical parents as stem cell donors. Such an approach will allow allogeneic transplantation of all patients in need. During the past years, it has become possible to optimize in vitro graft manipulation procedures making this transplant procedure safer and more efficient. Therefore this haploidentical transplantation procedure can now serve as a basis for further cellular immunotherapy in the treatment of malignant and non-malignant diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2011.04.005DOI Listing

Publication Analysis

Top Keywords

stem cell
16
cell transplantation
12
malignant non-malignant
8
identical donors
8
stem
5
transplantation
5
rapid immune
4
immune recovery
4
recovery low
4
low trm
4

Similar Publications

Introduction: Iron overload (IOL) accumulates in myelodysplastic syndromes (MDS) from expanded erythropoiesis and transfusions. Somatic mutations (SM) are frequent in MDS and stratify patient risk. MDS treatments reversing or limiting transfusion dependence are limited.

View Article and Find Full Text PDF

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) is poor. CD4 or CD8 conventional T (Tconv) cells are critically involved in mediating anti-leukemic immune responses to prevent relapse and detrimental GvHD.

View Article and Find Full Text PDF

Airway basal stem cell therapy for lung diseases: an emerging regenerative medicine strategy.

Stem Cell Res Ther

January 2025

Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Chronic pulmonary diseases pose a prominent health threat globally owing to their intricate pathogenesis and lack of effective reversal therapies. Nowadays, lung transplantation stands out as a feasible treatment option for patients with end-stage lung disease. Unfortunately, the use of this this option is limited by donor organ shortage and severe immunological rejection reactions.

View Article and Find Full Text PDF

NEAT1 regulates BMSCs aging through disruption of FGF2 nuclear transport.

Stem Cell Res Ther

January 2025

College & Hospital of Stomatology, Key Laboratory of Oral Diseases Research of Anhui Province, Anhui Medical University, Hefei, 230032, China.

Background: The aging of bone marrow mesenchymal stem cells (BMSCs) impairs bone tissue regeneration, contributing to skeletal disorders. LncRNA NEAT1 is considered as a proliferative inhibitory role during cellular senescence, but the relevant mechanisms remain insufficient. This study aims to elucidate how NEAT1 regulates mitotic proteins during BMSCs aging.

View Article and Find Full Text PDF

Background: Cancer remains a leading cause of death worldwide. Environmental factors, specifically endocrine-disrupting chemicals (EDCs), like phthalates, are increasingly being linked to cancer development. Phthalates, widely used in consumer products, can activate the aryl hydrocarbon receptor (AhR).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!